Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc. company information, Employees & Contact Information

Explore related pages

Canbridge Pharmaceuticals Inc. email format Canbridge Pharmaceuticals Inc. management contacts

Related company profiles:

CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.

Company Details

Employees
49
Founded
-
Address
4 Burlington Woods Dr, Burlington,massachusetts 01803,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
http://www.canbridgepharma.com
Keywords
Biotechnology, Pharma, Oncology, Rare Disease, Life Sciences.
HQ
Burlington, Massachusetts
Competitors
北海康成(北京)医药科技有限公司, Kailera Therapeutics, Amgen, Bristol Myers Squibb, Novo Nordisk, miLEAD Consulting, WuXi Biologics, Biogen, Bora Pharmaceuticals, BeiGene.
Looking for a particular Canbridge Pharmaceuticals Inc. employee's phone or email?

Canbridge Pharmaceuticals Inc. Questions

News

CANbridge Pharmaceuticals Completes US$98 Million Series D Financing Led by General Atlantic and WuXi AppTec - General Atlantic

CANbridge Pharmaceuticals Completes US$98 Million Series D Financing Led by General Atlantic and WuXi AppTec General Atlantic

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases - Business Wire

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases Business Wire

Companies like Canbridge Pharmaceuticals Inc.

Kailera Therapeutics logo - Similar company to Canbridge Pharmaceuticals Inc.

Kailera Therapeutics

121
miLEAD Consulting logo - Similar company to Canbridge Pharmaceuticals Inc.

Milead Consulting

66
Bora Pharmaceuticals logo - Similar company to Canbridge Pharmaceuticals Inc.

Bora Pharmaceuticals

660
BeiGene logo - Similar company to Canbridge Pharmaceuticals Inc.

Beigene

2.93K
Amgen logo - Similar company to Canbridge Pharmaceuticals Inc.

Amgen

35.77K
WuXi Biologics logo - Similar company to Canbridge Pharmaceuticals Inc.

Wuxi Biologics

2.92K
Novo Nordisk logo - Similar company to Canbridge Pharmaceuticals Inc.

Novo Nordisk

66.81K
北海康成(北京)医药科技有限公司 logo - Similar company to Canbridge Pharmaceuticals Inc.

北海康成(北京)医药科技有限公司

151
Bristol Myers Squibb logo - Similar company to Canbridge Pharmaceuticals Inc.

Bristol Myers Squibb

38.47K
Biogen logo - Similar company to Canbridge Pharmaceuticals Inc.

Biogen

7.60K

Top Canbridge Pharmaceuticals Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant